

HEPATITIS C CARE

NEWLY DIAGNOSED

Acute HCV – HCV ab + with detectable HCV RNA.

For patients with recent risk factors for HCV, monitor LFTs, HCV RNA for 6 months to assess for spontaneous clearance of hepatitis C.

Chronic HCV - HCV RNA detectable for at least 6 months. Needs LFTs, AFP every 6 months, CBC yearly.

WHO/WHEN TO TREAT

Diagnosis of chronic HCV – priority moderate/advanced fibrosis, HIV or HBV coinfecting. Children over the age of 12 should be treated in consultation with a liver disease specialist.

When is a patient ready for treatment?

When the provider has assessed patient to be adherent and patient agrees to complete medication regimen and follow up. If the patient has a substance use disorder (drug/EtOH), link to substance abuse treatment first.

FREQUENTLY USED DRUGS

Mavyret (Glecaprevir/Pibrentasvir) – All genotypes. Treatment naïve with no cirrhosis - 3 tabs daily for 8 weeks. Treatment naïve with compensated cirrhosis treat for 12 weeks.

Harvoni (Ledipasvir/Sofosbuvir) – Genotypes 1, 4, 5, & 6. Treatment naïve with no cirrhosis or compensated cirrhosis - 1 tab daily for 12 weeks.

Genotype 1, mild/mod fibrosis, treatment naïve, HCV RNA < 6 million IU/mL - 8 wks Harvoni.

Epclusa (Sofosbuvir/Velpatasvir) – All genotypes. Treatment naïve with no cirrhosis or with compensated cirrhosis – 1 tab daily for 12 weeks.

RETREATMENT

Consult Liver Disease Specialists before retreatment.

Test for NS5A resistance associated substitutions (RAS). QUEST Code 92447 (Genotype 1), QUEST Code 93325 (Genotype 3).

Available treatments include: Harvoni or Epclusa with ribavirin, Mavyret, or Vosevi.

LABS BEFORE TREATMENT

Immediately prior: Pregnancy test

Within 1 month: CBC with differential, CMP, PT/INR, HCV RNA

Within 3 months: Genotype confirmation, HBV DNA (if HBcAb or HBsAg +)

Within 6 months: AFP

Within 1 year: A fibrosis test: FibroSure, FibroTest, FibroSpect, or FibroScan. HIV screen, NS5A RAS for genotype 3 considering Eplusa.

Once: Hepatitis B surface antigen (HBsAg), Hepatitis B surface antibody (HBsAb), Hepatitis B core antibody (HBcAb), HAV total ab. Check Hepatitis A and B immunization status, vaccinate if needed.

LABS DURING TREATMENT

Week 4 - HCV RNA, CBC, CMP, Pregnancy test, HBV DNA (if HBcAb or sAg +)

Week 8 – HCV RNA (only if end of treatment), CBC, CMP, Pregnancy test, HBV DNA (if HBcAb or sAg +)

Week 12 – HCV RNA, CBC, CMP, Pregnancy test, HBV DNA (if HBcAb or sAg +)

FOLLOW UP AFTER TREATMENT

3 months post treatment completion – **HCV RNA to test for cure**, CBC, LFT, AFP

If advanced fibrosis or cirrhosis pretreatment – RUQ US and AFP every 6 months.

Cirrhosis – LFT, AFP every 6 months, CBC and PT/INR yearly and liver clinic visit yearly

GOT A QUESTION? WHO TO CALL

Liver Disease & Hepatitis Program – Call 907-729-1560 and ask for a nurse or provider.

Hannah Espera, RN 907-729-1599 hgfespera@anthc.org

Wileina Rhodes, RN 907-729-1569 wsrhodes@anthc.org

Annette Hewitt, ANP 907-729-1572 amhewitt@anthc.org

Lisa Townshend-Bulson, ANP Clinical Manager 907-729-1573 ltownshend@anthc.org

For more information and treatment forms, visit our website: www.anthc.org/hep